Why didn't Remdesivir apply for a patent first? Official response on the coronavirus

Why didn’t Remdesivir apply for a patent first? Official response on the coronavirus

According to domestic media reports about Remdesivir new coronavirus report, on February 5, at a press conference on the State Council’s joint prevention and control mechanism

A reporter asked: Remdesivir has recently attracted everyone’s attention. It arrived in China yesterday and entered the Phase III clinical trial.

What impact can clinical trials have on patients to allow wider applications? Second, the Wuhan Virus Research Institute found that the drug was effective, but why didn’t he first enter the clinic, but instead choose to publish a paper and apply for a patent first? what do you think about this?

National Health and Health Commission Response: A certain amount of the drug problem has been answered yesterday. From basic research to the clinical application of drugs, there is an established path to this. All actions must fully comply with the state drug approval process. As far as the first two issues are concerned, we too are worried about the situation.

Remdesivir on Coronavirus: Official website of the Wuhan Institute of Virology

According to the official website of the Wuhan Institute of Virology, Chinese Academy of Sciences, recently, the Wuhan Institute of Virology / Big Science Research Center for Biosafety, Chinese Academy of Sciences, and the National Institute for Emergency Control and Prevention of Drug Engineering Technology Research Institute of the Academy of Military Medical Sciences of the Chinese Academy of Sciences have jointly conducted research on the suppression of 2019 new types of coronavirus 2019-nCoV) made significant progress in drug screening.

Studies have shown that on VeroE6 cells. The half-effective concentration of Remdesivir (GS-5734) for 2019- nCoV EC50 = 0.77 UM (micro-litre per litre) is higher than that of SE129.

Chloroquine phosphate is above EC50 = 1.13m, SI88. He indicating that the above two drugs can effectively prevent 2019-nCoV infection at the cellular level. And their role in the human body so far. Could not get medical confirmation.

It is understood that Remdesivir (GS-5734) is a nucleoside analogue. Phase II and III clinical studies on Ebola hemorrhagic fever are currently being conducted in the DRC.

According to a joint statement from both sides, the drug Remdesivir, which has not yet been sold in China and has intellectual property barriers, has applied for a Chinese invention patent (new anti-2019 Coronavirus), The major countries of the Pass will enter the world through PCT (Patent Cooperation Agreement).